Drug intelligence / Profile preview

Oncozac

Development stage
Phase 2
Lead developer
PuraPharm
Administration
Oral
01

Overview

Oncozac is a herbal dietary supplement and proprietary Chinese medicine developed by PuraPharm Pharmaceuticals in collaboration with The Chinese University of Hong Kong. It contains ONCO-Z, a standardized extract of the mushroom Coriolus versicolor (Yunzhi), which was the first traditional Chinese medicinal ingredient verified by the United States Pharmacopeial Convention (USP) Dietary Ingredient Verification Program. The supplement contains Absorbable Peptidoglucan (APG), which is designed to stimulate the proliferation of immune cells, including white blood cells, bone marrow cells, and macrophages. Oncozac is primarily used as an adjunct therapy for oncology patients to strengthen immune function and alleviate side effects associated with surgery, radiotherapy, or chemotherapy. It is registered as a proprietary Chinese medicine in Hong Kong (HKC-10447) and is administered orally in capsule form.

Brand names
Oncozac
Other names
安固生Coriolus versicolor extractYunzhi extract
02

Targets

CLEC7A (Dectin-1)TLR4 (Toll-like receptor 4)

Beyond the preview

Go deeper on Oncozac.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Oncozac.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call